H ypertension has been declared as a world-wide epidemic and poses a substantial risk factor for cardiovascular diseases (CVDs), such as myocardial infarction and stroke; it is also a leading cause of chronic kidney disease. 1 Previous studies have identified many hypertension-related pathological processes that involve multiple organs. 2 Subsequently, numerous drugs and treatment strategies based on the mechanisms and signaling pathways that involved these processes have been developed. The increase in the number of adults with high blood pressure has occurred mainly in low-income and middle-income countries. 1 The prevalence of hypertension in high-income and some middle-income countries has even decreased. In the United States, the prevalence of hypertension, ≈29%, has not changed since 1999. 3 Blood pressure is regulated by many complex physiological pathways, and the impact of environment, behavior, and genetics on each pathway influences the actual levels and fluctuations of blood pressure. It can be said that the dynamic interactions among genetics, behavior, and environmental factors constitute the primary triggers. 4 When we talk about genetics, the first thing we think of is the disease caused by genetic mutations. Genome-wide association study have found single nucleotide polymorphisms of different genes associated with hypertension, such as angiotensinogen and angiotensin-converting enzyme, 5 and genes that regulate blood pressure effector genes. 6 From several hypertension-related biomarkers that have been identified, polymorphisms/mutations of genes only account for a small part of hypertension. 7, 8 This could be taken to indicate the need to examine other mechanisms in the pathogenesis of hypertension that do not change the DNA sequence, for example, epigenetics. Epigenetics dictates the phenotype without changing the genotype, that is, no modifications of the DNA sequences. Multiple physiological and pathological processes including hypertension are regulated by epigenetic phenomena, like histone modification, DNA methylation, chromatin remodeling, and especially, noncoding RNA (ncRNA)-mediated targeting of various genes, 9 for example, G-protein-coupled receptor kinase type 4 phosphorylates histone deacetylase type 1, promoting its nuclear export to the cytoplasm, resulting in increased angiotensin II receptor type 1 (AGTR1) expression and greater pressor response to angiotensin II. 10 This review aims to provide an overview of the likely role of ncRNAs in the development of hypertension, as well as advances in ncRNA-based diagnoses and therapeutic approaches. A better understanding of the ncRNA-based molecular mechanisms of the pathogenesis of hypertension is important for the prevention and treatment of hypertension and its complications.
Noncoding RNA
Historically, protein-coding genes, with proteins as the final gene products, have been viewed to mediate the phenotype and biological function of any given cell. However, more and more recent studies have shown that ncRNAs participate in the regulation of the expression of protein-coding genes and therefore play essential roles in many biological processes. These findings have uncovered that ncRNAs orchestrate a hidden layer of gene regulation network. 11 These ncRNAs have emerged as dynamic managers that influence the interaction between DNA and the environment that characterizes epigenetics.
Generally, ncRNAs are generated in the nucleus, transcribed by RNA polymerase II , giving rise to a long precursor mRNA, and the main processing mechanism for precursor mRNA transcript is processed by the spliceosome. Apart from the similarities, there are many differences between different types of ncRNAs in biogenesis and processing, which has been recently reviewed elsewhere. 12 Based on size, ncRNAs are classified by the size as the small (≈20 nucleotides), intermediate (≈20-200 nucleotides), or long (>200 nucleotides). Small ncRNAs (≈20 nucleotides) include piwi-interacting RNAs, the largest class of ncRNAs, small interfering RNAs, guide RNA, and microRNAs. 13 Intermediate ncRNAs (≈20-200 nucleotides) are involved in splicing during protein synthesis and include nucleolar RNAs that modify ribosome RNA, transcription start site-associated RNAs, and promoterassociated small RNAs. 13 The rest of the ncRNAs, that are >200 nucleotides, have been grouped into long noncoding RNAs (lncRNAs). Unlike microRNA, lncRNAs have numerous functions in cis and in trans by regulating gene expression with transcription and translation, splicing, chromatin imprinting, and cell cycle development. lncRNAs can silence multiple genes through their interaction with chromatin, or even recruit transcriptional factors to target promoters and induce transcription, indicating that they are central to the epigenetic control of gene expression. The 3′-and 5′-ends of linear RNA transcripts can join and form a loop to make circular RNA (circRNA), a newly identified group of ncRNA, which exhibits stability and high conservation and plays a role in many biological processes.
The pathogenesis of hypertension entails a complex interaction of different organs and systems, including an overactivation (eg, renin-angiotensin-aldosterone system, central nervous system, sympathetic nervous systems, central nervous and peripheral nervous systems, including renal nerves) or underactivation (eg, parasympathetic nervous system, renal dopamine, atrial natriuretic peptide) of systems that increase vascular reactivity and sodium retention, remodeling of blood vessels, and dysfunction of vascular endothelia. Gastrorenal axis 15 and the lymphatic system 16 are also reported to be involved in the salt and water homeostasis regulatory network, adding to the importance of multiorgan crosstalk in the pathogenesis of hypertension. NcRNAs, which are comprehensively involved in the development of hypertension, are promising diagnostic biomarkers and therapeutic targets of hypertension. A summary of the relationship between hypertension and ncRNAs is shown in Figure 1 .
Role of ncRNA in Hypertension Role of MicroRNA in Hypertension

MicroRNA in Body Fluids With Clinical Diagnostic Potential
The discovery of biomarkers is an important part of the diagnosis of disease. In addition to high sensitivity and specificity, an ideal biomarker should meet the following criteria: (1) good accessibility, samples must be easily accessible through minimally invasive methods, such as those from the body fluids; (2) stability, the biomarkers should have a relative long half-life in the sample, which facilitates the delivery, storage, and analysis of samples; and (3) robust reliability, the detection methods of biomarkers should be rapid, accurate, sensitive, and inexpensive, which are essential for point-of-care and wide-spread utilization. At present, the vast majority of clinically applicable biomarkers are macromolecular proteins or small molecule metabolites. In addition, in recent years, nucleic acid biomarkers, especially ncRNAs, have achieved rapid development because of some inherent characteristics (vide infra).
MicroRNAs have been isolated from circulating cells, including peripheral blood cells, and multiple body fluids, such as plasma, serum, and urine. The reason why microRNAs can exist or even detected in body fluids is mainly because they are enveloped by extracellular vesicles and thus, protected from endogenous RNase degradation, and are highly stable even when exposed to extreme conditions. 17 Because of these characteristics, microRNAs in extracellular vesicles, as biomarkers, have received more and more attention. MicroRNA represents promising novel options as a diagnostic approach in many diseases, such as in cancer 18 and nervous system diseases. 19 Recently, some microRNAs have been found to be biomarkers for some CVDs. For example, miR-208a, miR-1, miR-499, and miR-133 in plasma have been identified as biomarkers with both high sensitivity and specificity for acute myocardial infarction diagnosis. 20 Progress has been made in relating circulating microRNAs to hypertension. Microarray studies have found 3 upregulated microRNAs (miR-425, miR-505, and miR-210) in plasma from hypertensive patients. Among these 3 microRNAs, plasma miR-505 has been reported to consistently elevated in all hypertensives cohorts. 21 In addition, 9 microRNAs were upregulated and 18 microRNAs were downregulated, respectively, in the plasma of hypertensive patients. 22 Upregulated miR-296-5p, miR-let-7e, and hcmv-miR-UL112, a human cytomegalovirus-encoded microRNA which play a role in human cytomegalovirus infection and latency, were all validated in essential hypertensive patients. 22 Besides of hypertension in general, different microRNAs have been reported to be differentially increased in saltsensitive and salt-resistant hypertension. A study, involving 6 salt-sensitive and 6 salt-resistant hypertensive patients, detected 2 dysregulated microRNAs (miR-361-5p and miR-362-5p) in whole blood samples; both were validated in a larger cohort of 91 subjects. The area under the curve determined by receptor operating characteristic analysis for hsa-miR-361-5p was 0.793, which makes hsa-miR-361-5p combined with the dietary history the preferred marker for salt-sensitive hypertension. 23 Moreover, the expressions of microRNAs isolated from urine exosomes may also be biomarkers of salt-sensitive, inverse salt-sensitive, and saltresistant hypertension. 24 MiR-4516, probably expressed in renal tubule cells, among 45 urinary exosome-dysregulated microRNAs, was able to distinguish salt sensitivity from Multiple organs, tissues, and systems, such as brain, kidney, heart, gastrointestinal tract, lymph, and artery (especially endothelial cell and vascular smooth muscle cell), participate in the regulatory network of hypertension (green gear) and complex cross-talks found in different tissues (yellow lines in green gear). Noncoding RNAs, including microRNA (miRNA), long noncoding RNA (lncRNA), circular RNA (circRNA), and tRNA (yellow gear), by themselves or by interaction with others (yellow lines in yellow gear), guide RNA (gRNA) and gene editing technologies that can be directly applied to the functional regulation of these ncRNAs (blue arrows in the yellow gear), are engaged in the regulation of blood pressurerelated tissue function (yellow and green arrows). CNS indicates central nervous system. inverse salt sensitivity, a condition in which the blood pressure is increased by a low-sodium diet. 24 However, these findings require verification in a larger cohort, as should be the case in studies of dysregulated circulating microRNA expression in hypertension. The concrete evidence and diagnostic value of microRNA to serve as a biomarker in hypertension need further elucidation. The blood pressure-related microRNAs in body fluids with [21] [22] [23] [24] or without [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] verification in patients were summarized in Table 1 .
Solid Evidence of Dysregulated MicroRNAs in the Pathogenesis of Hypertension
In addition to differentially expressed microRNAs in body fluids, many dysregulated microRNAs also have been found in various human tissues and genetic animal models of hypertension. The roles of these microRNAs in the regulation of blood pressure have been functionally verified.
Dicer, which transfers precursor microRNAs to mature forms, has been shown to be a key player not only in biogenesis and processing of microRNA but also to the progression of hypertension. A series of studies deleted dicer in vivo and in vitro to explore its role in hypertensive phenotype-related microRNAs. Juxtaglomerular cells are key in renin production; mice with Dicer conditionally deleted from renin-producing cells reduced the number of juxtaglomerular cells, decreased renin gene (Ren1 and Ren2), plasma renin, and blood pressure. 36 Deficiency of Dicer in vascular smooth muscle cells (VSMCs) results in a decrease in the vasoconstrictive ability of resistance arteries, aortic medial thickness, 37 and both systolic and diastolic blood pressures. 38 The ability of exercise to lower blood pressure, which is well-known, may be caused by the release of endogenous substances from the skeletal muscle, including microRNA. CIMT indicates carotid intima-media thickness; iCIMT, increased CIMT; nCIMT, normal CIMT; sPE, severe preeclampsia; and WCH, white coat hypertension.
Spontaneously hypertensive rats (SHRs) that swam for 10 weeks had decreased blood pressures, compared with those that did not. Moreover, soleus muscle miR-126 was upregulated to normal whereas miR-16 and miR-21 were downregulated in the exercising SHRs. 39 Plasma and urine miR-21 levels are increased in hypertensive patients. 40, 41 MiR-21 mimic using recombinant adeno-associated virus-mediated delivery system was sufficient to reduce blood pressure in SHRs. 40 Mechanically, computational prediction and biochemical studies showed that microRNA-21 could be targeted directly to mitochondrial DNA (mtDNA)-encoded cytochrome b and positively modulate mtDNA-encoded cytochrome b translation in mitochondria, and mtDNA-encoded cytochrome b has been reported to be important in elevating reactive oxygen species production in heart, 40 but the direct relationship between mtDNA-encoded cytochrome b and hypertension still needs to be further studied.
Genome-wide differences in microRNAs in the renal cortex and medulla of hypertensive and normotensive subjects using microarray have been reported. 42 Eleven and 13 microRNAs were differentially expressed in the renal medulla and cortex, respectively. The differentially expressed microRNAs were then identified in 22 hypertensives and 16 normotensives. Two downregulated microRNAs, miR-181a and miR-663, in the renal medulla samples were identified, using in silico analyses. In addition, miR-181 was found to bind directly to the 3′ untranslated region (UTR) of human renin mRNA and reduce renin secretion. The Schlager BHP/2J mouse, which is a neurogenic model of hypertension, was used to explore the function of miR-181a in hypertension. The investigators found that miR-181a mimic treatment decreased the blood pressure and renin mRNA level of renin in BHP/2J mouse. 42, 43 To identify vascular-related microRNAs in the development of hypertension, small RNA deep sequencing was performed in cultured human microvascular endothelial cells. The 50 most abundant microRNAs were identified and 30 of them with predicted target mRNAs relevant to hypertension. A functional screen of these dysregulated microRNAs using anti-miR oligonucleotides system in in vivo experiments showed that anti-miR-21 did not affect the blood pressure of C57Bl/6 mice fed 0.4% NaCl but decreased the blood pressure in those fed a 4% NaCl diet. 44 As aforementioned, miR-21 is increased in plasma and urine 40, 41 ; it is also increased in peripheral blood mononuclear cells of hypertensive patients. 35 However, in the SHR, miR-21 mimic decreased the blood pressure, 40 the opposite of that found in salt-sensitive C57Bl/6 mice 44 which could be taken to indicate that microRNA function can be influenced by genes and diet. Chromogranin A regulates blood pressure, and disruption of miR-22 can regulate its expression. The intraperitoneal injection of miR-22 antagomir has been shown to decrease the blood pressure of SHRs. 45 The expressions of miR-143, miR-145, and miR-133 are decreased in peripheral blood mononuclear cells from hypertensive patients. 35 Mice lacking both miR-143 and miR-145 have low blood pressure caused by a reduction in vascular tone. 46 As stated above, these apparently contradictory findings could be taken to indicate that the function of microRNAs can be influenced by factors that need to be discovered, at least in the context of blood pressure regulation.
Insufficient Evidence of a Role of Dysregulated-MicroRNAs in Hypertension
As indicated above, only a small fraction of functional microRNAs have been shown to have a direct effect blood pressure in vivo. MicroRNAs are involved in the regulatory network that causes hypertension. MicroRNAs participate in these processes by regulating many downstream molecular targets via different modes of action, mainly including binding to the UTR of downstream genes. However, it is still unclear whether actual alteration of the expression of these microRNAs can affect the blood pressure in vivo which should be the subject of future studies.
Renin-Angiotensin-Aldosterone System
The role of the renin-angiotensin-aldosterone system in the regulation of blood pressure is well-known. Reninangiotensin-aldosterone system-related microRNAs that are dysregulated in humans affect blood pressure in animal models. 36 Conditional Dicer knockdown in a human adrenocortical cell line increased the expression of CYP11B1 and CYP11B2 genes, which are responsible for the final stages of cortisol and aldosterone biosynthesis, respectively. An in vitro study showed that miR-24, a Dicer-dependent microRNA, decreased CYP11B1 and CYP11B2 mRNA expression by binding to their 3′UTR. This resulted in a decrease in cortisol and aldosterone production. 47 A study focused on NR3C2, the mineralocorticoid receptor, which mediates aldosterone-induced sodium reabsorption. 48 The binding of miR-124 and miR-135a to the 3′UTR of NR3C2 has been shown to contribute to the translational but not the transcriptional regulation of NR3C2. 49 miR-21, the concentration of which is increased in the plasma, urine, and peripheral blood mononuclear cells of hypertensive patients, 35, 40, 41 has also been reported to increase aldosterone secretion in angiotensin II-treated human adrenocortical cells. 50 This miR-21 effect could explain why anti-miR21 decreases the blood pressure of salt-sensitive mice. 44 miR-155 binding to the 3′UTR of AGTR1 downregulates its expression. miR-155 expression in peripheral mononuclear blood cells is decreased in humans with the AGTR1 CC genotype. AGTR1 protein but not mRNA is higher in hypertensive than normotensive subjects with the AGTR1 CC genotype, suggesting the AGTR1 CC genotype makes it inaccessible for miR-155 to decrease AGTR1 gene expression. 51 The increased expression of AGTR1 in hypertension has also been related to decreased renal expression of histone deacetylase 1 caused by G protein-coupled receptor type 4 gene variants. 10 MiR-483-3p, identified from microarray data of renal and smooth muscle cells and hearts of humans, rats, and mice, was found to suppress the expression of renin-angiotensin-aldosterone system-related proteins, such as AGTR2, AGT, angiotensin-converting enzyme 1, and angiotensin-converting enzyme 2, by interacting with the 3′-UTRs of these renin-angiotensin-aldosterone system genes. 53 Hypertensive patients have polymorphisms of dopamine receptors. 54 SHRs have decreased renal D 3 R expression. 55 We have reported that let-7d decreases D 3 R expression by decreasing its transcription via DNMTdependent DNA methylation and histone modification in immortalized rat renal proximal tubule cells. 56 MiR-217 has been shown to exert the protective effects of D 2 R on fibrosis in human renal proximal tubule cells by decreasing the expression of transforming growth factor-β1. 57 MicroRNA profiling in the Dah1 salt-sensitive rat showed that 2 microRNAs (miR-29b and miR-302d) were downregulated while 3 were upregulated (miR-365, miR-211, and miR15b), relative to SS-13BN controls. MiR-29b is a key regulator of 20 collagen-and several extracellular matrix-related genes, such as matrix metalloproteinase 2 and integrin β1. MiR-29b may participate in the protection from renal injury through the extracellular matrix-associated pathway, without changing the blood pressure. 58 
Arterial Dysfunction
Vascular endothelial dysfunction is another key factor in the initiation and maintenance of hypertension. Impaired vasodilatation, inflammation, and oxidative/nitrosative stress in different cell types within many organs, including vascular smooth muscles and vascular endothelia, are observed in hypertension. MicroRNAs regulate nitric oxide (NO) and reactive oxygen species levels in the vascular endothelium. For example, the 50 most abundant microRNAs were identified in cultured human microvascular endothelial cells. 58 In these cells, the expression of 14 mRNAs (ADM, ATP2B1, FURIN, FGF5, GOSR2, JAG1, SH2B3, TBX3, ADRA1B, ADRA2A, ADRA2B, ADRB1, EDNRB, and NOX4) was suppressed by specific microRNA. Inhibition of the miR-92 family, targeting NOX4 mRNA, increased H 2 O 2 release from endothelial cells. The results suggest that these microRNAmRNA pairs are involved in the vascular-based hypertension regulatory network. 59 Other microRNAs, such as miR-155 and the miR-221/222 cluster, can reduce the mRNA expression of eNOS (endothelial NO synthase) by binding directly to the 3′UTR of eNOS. [60] [61] [62] In addition, a novel C/T polymorphism in the 3′UTR of SLC7A1, a gene involved in the transport of arginine needed for NO production, is associated with hypertension. The T allele results in increased 3′UTR length and facilitates the binding of miR-122 which in turn inhibits SLC7A1 expression. 63 MiR-145 has also been reported to be increased in the aorta of SHRs; silencing miR-145 in rat vascular endothelial cells increased the expression of SLC7A1. 64 MiR-217 was reported as an inhibitor of eNOS through Sirt1, leading to the senescence of endothelial cells and contributing to development of hypertension. 65 Several microRNAs expressed in VSMCs have also been reported. 66 As stated above, miR-21 levels are increased in the plasma, urine, and peripheral blood mononuclear cells in hypertensive patients 35, 40, 41 and that miR-21 increases the expression of the mineralocorticoid receptor, NR3C2, in angiotensin II-treated human adrenocortical cells. 50 MiR-21 has also been reported to increase cell proliferation and decrease cell apoptosis in aortic VSMCs; miR-21 expression is increased the balloon-injured rat carotid artery. 67 This study adds to the notion that an increase in miR-21 causes hypertension. 44 Why miR-21 is antihypertensive in the SHR remains to be determined. 40 MiR-320 and miR-26b were up-and downregulated, respectively, among 37 dysregulated microRNAs in the aorta of Dah1 salt-sensitive rats fed 8% NaCl for 4 weeks. Both miR-320 inhibitor and miR-26 mimic prevented VSMCs hypertrophy by targeting insulin growth factor-1 receptor (miR-320) and phosphatase and tensin homolog mRNA. 68 Other reports show that miR-34b could control cell cycle progression and proliferation of VSMCs by targeting cyclin-dependent kinase 6. 69 MiR-130a has also been shown to promote angiotensin II-induced proliferation of VSMCs by directly targeting the growth arrest-specific homeobox, a VSMC proliferation inhibitor. 70 MiR-424/322 71 and miR-365 72 also participate in cell cycle arrest and proliferation of VSMCs in several stress-induced cell and animal models via multiple singling pathways, suggesting fundamental roles of microRNAs in VSMC function and blood pressure regulation.
Increasing evidence suggests that vascular adventitial remodeling is a complex process, which leading to arterial stiffness and loss of elasticity of the vessel wall, and participate in the pathophysiology of many vascular diseases, including hypertension. 73 The adventitial fibroblasts transform into a myofibroblast phenotype is speculated to be a critical step in this process. 73 It has been shown that microRNAs can involve in the adventitial remodeling and adventitial fibroblasts phenotypic transdifferentiation. MiR-487b was the most abundantly upregulated microRNA in the adventitia from aorta of angiotensin II-induced hypertensive Sprague-Dawley rats. 74 Inhibition of miR-487b in human umbilical arterial adventitial fibroblasts increased cell survival and protected adventitial fibroblasts. 74 MiR-155 has also been shown to decrease AGTR1 protein expression and attenuates angiotensin IIinduced phenotypic differentiation in rat aortic adventitial fibroblasts, which suggests miR-155-mediated target gene could be involved in regulating adventitial fibroblast differentiation and vascular adventitial remodeling. 75 However, the direct evidence of miR-487 and miR-155 in regulating blood pressure still needs to be further studied. The microRNA findings in tissues and cells are summarized in Table 2 .
Role of lncRNA in Hypertension
The expression and conservation among species of lncRNAs are much lower than microRNAs, and the molecular mechanisms of lncRNA function are not yet fully understood. Research on the relationship between lncRNA and CVDs, especially hypertension, is very limited. However, some lncRNAs have been shown to play a role in the physiological and pathological regulation of blood pressure. These lncRNAs can be detected in various body fluids from hypertensive patients, indicating their potential as diagnostic and therapeutic targets for hypertension.
lncRNAs With Clinical Diagnostic Potential
Multiple blood pressure-related loci have been found in humans using genome-wide association study, including the lncRNA H19 locus, which is associated with systolic blood pressure. 76 Moreover, 4 single nucleotide polymorphisms (rs10757274, rs2383207, rs10757278, and rs1333049), located on a lncRNA, CDKN2B-AS1 were found to confer increased susceptibility to the development of hypertension. 77 Biomarker-like circulating lncRNAs have also been detected in CVDs. Using a microarray-based lncRNA expression profiling, we found 86 differentially expressed lncRNAs in plasma and peripheral blood cells from 15 patients with coronary artery disease and 15 control subjects. After choosing a consistent criterion and confirmed in another larger cohort, CoroMarker, 78 LncPPARδ, 79 and OTTHUMT00000387022 80 were proved as stable, sensitive, and specific biomarkers for coronary artery disease. Plasma lncRNA growth arrestspecific 5 (GAS5) has also been reported to be decreased in patients with coronary artery disease. 81 However, except in pulmonary arterial hypertension, very few circulating lncRNAs were reported in essential hypertension. A recently discovered lncRNA-AK098656, a human-specific expressed lncRNA, has been verified to be upregulated while lncRNA-AK125261 was downregulated in the plasma of hypertensive patients, 82 suggesting a promising future of lncRNA-based biomarkers in hypertension. 83 Functional lncRNAs in Human, Animal, and Cell Models Several lncRNAs, discovered using deep sequencing technology and functional verification, have be studied in vitro. lncRNA-AK098656, which as stated above, is markedly upregulated in the plasma of hypertensive patients, is predominantly expressed in VSMCs. AK098656 enhanced the proliferation and migration of VSMCs, resulting in a phenotype switching to VSMC proliferation and migration by binding to MYH11 (myosin heavy chain-11) and FN1 (fibronectin-1), promoting their degradation. AK098656 transgenic rats, at 10 weeks of age became hypertensive, associated decreased expression of MYH11, FN1, and α-smooth muscle actin in the thoracic aorta and renal and superior mesenteric arteries. The lumens ACE-1 indicates angiotensin-converting enzyme 1; AGTR1, angiotensin II receptor type 1; CDK6, cyclin-dependent kinase 6; CYP11B, 11β-hydroxylase; DSS, Dahl salt sensitive; GAX, growth arrest-specific homeobox; HASMC, primary human aortic smooth muscle cells; HEK-293, human embryonic kidney; IGF1R, insulin growth factor-1 receptor; IRS1, insulin receptor substrate 1; Itgb1, integrin β1; Mmp2, matrix metalloproteinase 2; NR3C2, mineralocorticoid receptor gene; PBMC, peripheral blood mononuclear cell; PTEN, phosphatase and tensin homolog on chromosome 10; RAAS, renin-angiotensin-aldosterone system; RASMC, rat aortic smooth muscle cell; SHR, spontaneously hypertensive rats; SirT1, silent information regulator 1; VSMC, vascular smooth muscle cell; and WKY, Wistar-Kyoto.
of the renal and mesenteric arteries were also decreased in AK098656 transgenic rats. 82 A global transcriptome-based screening of the aorta found 68 upregulated and 167 downregulated lncRNAs in SHRs, compared with Wistar-Kyoto rats. The expression of lncRNA XR007793 was found to be increased, the expression of which in VSMCs can be induced by a 15% (pathological hypertensive cyclic strain) cyclic strain. The silencing of lncRNA XR007793 in VSMCs resulted in a reduction of proliferation and migration and inhibition of the gene expression of signal transducers and activators of transcription 2, LIM domain only 2, and interferon regulatory factor 7. Therefore, XR007793 is likely to be involved in the vascular remodeling during hypertension. 84 A novel predicted lncRNA, named Rffl-lnc1, is implicated in regulating QT interval and blood pressure in the rat. CRISPR/Cas9-based disruption of the rat Rffl-lnc1 locus resulted in elevated blood pressure, accompanied by short QT intervals; targeted knockin rescued these phenotypes. 85 Another comprehensive bioinformatics analysis based on deep sequencing identified 273 dysregulated lncRNAs in Dahl salt-sensitive rats, relative to Dahl salt-resistant rats and 749 dysregulated lncRNAs in Dahl saltsensitive relative to SHR. Four mRNA targets, Asb3, Chac2, Pex11b, and Sp5, were found to be similarly expressed as the lncRNAs, indicating that these lncRNA-mRNA networks could contribute to the development of hypertension. 86 There are also some lncRNAs involved in the regulation of biological functions of VSMC and endothelial cells, but the relationship between these lncRNAs and blood pressure is not yet clear. RNA-sequencing of angiotensin II-treated VSMCs found that lnc-Ang362, as the host transcript for miR-221 and miR-222, is involved in VSMC proliferation. 87 Moreover, human sequencing data have revealed a vascular cell-enriched lncRNA named as smooth muscle and endothelial cell-enriched migration/ differentiation-associated lncRNA, whose knockdown in vitro results in the loss of myocardin and smooth muscle contractile genes but an increase in promigratory genes. Smooth muscle and endothelial cell-enriched migration/differentiation-associated lncRNA was shown to be a negative regulator of VSMC migration. 88 Identification of endothelial cell-related lncRNAs is still limited, but the lnc MALAT1 impairs promigratory response but increases endothelial proliferation through histone modification. 89 GAS5 was mainly expressed in endothelial cells and VSMCs; clinic study showed that the expression of GAS5 was decreased in the plasma of patients with hypertension. 90 Downregulation of GAS5 by short-hairpin RNA injection increased the blood pressure of SHRs. 90 In vitro studies shows that GAS5 knockdown leads to increased viability and proliferation of endothelial cells and affects proliferation, phenotypic switching of VSMCs, thus, regulated the remodeling of arteries. As an important pathological feature of hypertension, vascular remodeling in turn increased vascular resistance and induced hypertension. 90 It suggests GAS5 involved in this Hypertension-Vascular remodeling-Hypertension feedback loop. Mechanically, GAS5 regulates vascular remodeling through direct binding to β-catenin and affecting its nuclear translocation and downstream targets. 90 But the direct evidence of GAS5 regulating blood pressure in human still needs to be further studied. LncRNAs relevant to blood pressure and hypertension are summarized in Tables 3 and 4 .
Other ncRNAs Involved in Hypertension
The role of other ncRNA like circRNA and tRNA in diseases has attained significant importance in recent years. However, their roles in CVDs, especially hypertension, are rarely reported. Except for the differential expression of these ncRNAs in hypertensive patients and potential function in cell assays, there is no unambiguous evidence that these ncRNAs can regulate blood pressure.
CircRNAs are noncanonically spliced or back spliced RNAs that form a covalently closed loop when the 3′ tail end of a downstream exon is linked with 5′ head of an upstream exon. CircRNAs mostly regulate gene regulation in a posttranscriptional way by acting as microRNA sponge. 91 A circRNA, hsa-circ-0005870, was been found to be downregulated in the plasma of hypertensive patients. 92 However, how it regulates blood pressure was not determined. hsa-circ-000595 was found to be increased in aorta with aneurysm. hsa-circ-000595 knockdown attenuated the apoptosis rate of human aortic smooth muscle cells by sponging miR-19a, a member of the miR-17-92 cluster, involved in cell viability in cancer. 93 CircRNAs may be biomarkers for the diagnosis of hypertension, and circRNA-microRNA-mRNA networks may provide potential mechanisms for hypertension.
tRNA carries amino acids to the growing polypeptide chain during the translation of mRNA. Pedigree studies of families heavily affected by maternally inherited hypertension have identified several pathogenic mutations in tRNA, which usually result in mitochondria dysfunction characterized by oxidative stress, respiratory deficiency, and ATP insufficiency. For example, the m.4435A→3G mutation in mitochondrial tRNA Met alters the structure and biological function of mitochondria whereas the m.15909A > G variant in tRNA Thr and the m.3253T→C mutation in tRNA Leu(UUR) disrupt a highly conserved base pairing (11U-24A) or uridine at position 22 in the D-stem of their tRNA, respectively. [94] [95] [96] Considering that all tRNAs are mitochondrial genome encoded and mutations in mitochondria are maternally inherited, such mutated tRNAs may be involved in inherited hypertension. A summary of the newly identified ncRNAs in the key biological process of hypertension pathogenesis is shown in Figure 2 .
Research Prospects of ncRNA
The study of epigenetics, especially ncRNAs, is changing rapidly. However, there are still many problems that need to be solved to understand and prove the role ncRNAs in disease. In the light of the continuous improvement in technology, new ideas and methods in studies of the role of ncRNAs in hypertension should be forthcoming.
Bioinformatics
The biological and molecular functions of most CVD-related noncoding transcripts remain largely unknown because of low conservation, complex secondary structure, and cell type specificity. Although great progress has been made, there are still many challenges in ncRNAs investigations currently. Through high-throughput screening, more and more differentially expressed ncRNAs can be found. However, the function of ncRNA is diverse, and the RNA-RNA, RNA-DNA, RNA-protein interactions constitute the regulatory network of ncRNA. Bioinformatics can provide hints on how to determine the downstream targets or binding proteins of ncRNA and how these ncRNAs work. Such as specialized database development, functional prediction, and interactive network reconstruction are valuable tools in ncRNA research. Using these bioinformatic tools, genes associated with diseases, like essential hypertension, can be investigated from a system perspective, which enables us to create a network graph for disease. 
Next-Generation Sequencing
Many advances in medical research, including those related to CVDs, have benefited from the rapid development of sequencing technologies. RNA-sequencing has improved the genome-wide identification and expression profiling of ncRNAs; several well-studied ncRNAs, like Bvht 98 and lincRNA-p21, 99 were discovered through this technology. RNA-sequencing, chromatin immunoprecipitation sequencing, RNA-immunoprecipitation sequencing, and crosslink immunoprecipitation sequencing 100 
Coding Potential of ncRNAs
Recently, more and more attention has been paid to the coding ability of ncRNAs. NcRNA, especially lncRNA and circRNA, have open reading frame just like mRNA; ribosome display technology shows not only mRNAs but also ncRNAs directly binding to the ribosome. 100 However, lncRNAs do not encode proteins. 102 All these pieces of information obtained by innovative technology encourage scientists to explore the new protein and polypeptide coding from ncRNAs. DWORF, a peptide of 34 amino acids, has α-SMA indicates α-smooth muscle actin; ECM, extracellular matrix; FN-1, fibronectin-1; GAS5, growth arrest-specific 5; irf7, interferon regulatory factor 7; lmo2, LIM domain only 2; lncRNA, long noncoding RNA; MYH11, myosin heavy chain-11; SENCR, smooth muscle and endothelial cell-enriched migration/ differentiation-associated long noncoding RNA; SHR, spontaneously hypertensive rats; SNP, single nucleotide polymorphism; stat2, signal transducers and activators of transcription 2; VSMC, vascular smooth muscle cell; and WKY, Wistar-Kyoto.
been identified from a muscle-specific lncRNA, which can enhance SERCA activity by displacing the SERCA inhibitors, thereby favoring heart contractility in mammals. 103 Similarly, myoregulin, a conserved micropeptide robustly expressed in skeletal muscles, is an important regulator of skeletal muscle physiology and improves exercise performance. 104 These findings open new ways to understand cardiac function and pathology and show that proteins/peptides from ncRNAs can act as regulators in different cardiovascular biological processes.
ncRNA-Based Therapeutic Strategies
Clinical translation of ncRNAs as therapeutic drugs has recently been highlighted, which involves utilization of inhibition and overexpression approaches for delivering ncRNAs in vivo. So far, modified ncRNA-based strategies, involving microRNA antagomir (LNA oligonucleotide), microRNA mimics, antisense oligonucleotide, and small interfering RNA, have been used for the treatment of many diseases. For instance, Miravirsen (miR-122 targeting) is the first anti-microRNA tested preclinically and now has entered phase 2 clinical trials for hepatitis C virus infection. 105 This was followed by the first microRNA mimic MRX34 (miR-RX34), encapsulated in a liposomal nanoparticle formulation, which has entered phase I trials as a potential treatment of epithelial carcinomas. 106 In CVDs, miR-25, which was cardiac specifically overexpressed using adeno-associated virus 9, decreased myocardial contractility. By contrast, miR-25 antagomir improved cardiac function and increased survival rate in a mouse model of heart failure. 107 Antagomir against miR-22 could lower blood pressure by18 mm Hg in SHRs. 45 However, the low delivery efficacy to the vasculature impedes their application in vascular-related diseases. To address this problem, novel delivery systems like adeno-associated virus, 108 lipoprotein-based drug carriers, and nanoparticle drug carriers might be an option. 109 These tools have brought hope for microRNA-based treatment of hypertension.
lncRNA may also be difficult to deliver to the desired tissue because of its more complicated structure, function, and mechanisms of action. 110 lncRNAs are also usually retained in the nucleus, making them hard to be targeted by small Figure 2 . Newly identified noncoding RNAs (ncRNAs) in the key biological process of hypertension pathogenesis. A, Samples from hypertensive patients, animal, and cell models are collected. B and C, High-throughput screening is preformed, and many dysregulated ncRNAs are found using microarray or nextgeneration sequencing. Some microRNAs (miRNAs; D), long noncoding RNAs (lncRNAs), and circular RNAs (circRNAs; E) among the dysregulated ncRNAs can be detected in body fluids of human as potential biomarkers. Some others play roles in the key biological process, such as renin-angiotensin-aldosterone system (RAAS) and vascular dysfunction of hypertension. VSMC indicates vascular smooth muscle cell.
interfering RNA. 111 Antisense oligonucleotide GapmeR system 112 -mediated nuclear lncRNA knockdown shows promise to solve this problem. Another point that cannot be ignored is the fact that lncRNAs are poorly conserved among species, 113 which hinders the translation of non-human studies to humans. One possible solution might to assess the therapeutic roles of the disease-associated lncRNAs in preclinical disease animal models and evaluate them in the human-based model systems.
Conclusions
In light of identifying new regulatory network of ncRNAs, much more work is needed to show their potential role and involvement in hypertension. The findings of dysregulated ncRNAs using next-generation sequencing technology during hypertension highlight the promise of ncRNAs, including circRNAs, as diagnostic biomarkers. In addition, innovations, such as CRISPR/Cas9 114 -mediated gene editing and new vehicles such as adeno-associated virus 9 115 for in vivo delivery, further facilitate the functional screening of novel ncRNAs and deepen the understanding of their biology. Ultimately, these would lead to the individualized treatment of hypertension and its complications personalized medicine.
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